- Home
- POOL vs ENVB Comparison
POOL vs ENVB Comparison
Compare POOL & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POOL
- ENVB
- Stock Information
- Founded
- POOL 1993
- ENVB 1994
- Country
- POOL United States
- ENVB United States
- Employees
- POOL N/A
- ENVB N/A
- Industry
- POOL Industrial Specialties
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- POOL Consumer Discretionary
- ENVB Health Care
- Exchange
- POOL Nasdaq
- ENVB Nasdaq
- Market Cap
- POOL N/A
- ENVB 3.2M
- IPO Year
- POOL 1995
- ENVB N/A
- Fundamental
- Price
- POOL $301.64
- ENVB $1.27
- Analyst Decision
- POOL Hold
- ENVB Strong Buy
- Analyst Count
- POOL 9
- ENVB 1
- Target Price
- POOL $341.22
- ENVB $10.00
- AVG Volume (30 Days)
- POOL 521.6K
- ENVB 43.0K
- Earning Date
- POOL 04-24-2025
- ENVB 05-19-2025
- Dividend Yield
- POOL 1.59%
- ENVB N/A
- EPS Growth
- POOL N/A
- ENVB N/A
- EPS
- POOL 10.70
- ENVB N/A
- Revenue
- POOL $5,261,669,000.00
- ENVB N/A
- Revenue This Year
- POOL $2.96
- ENVB N/A
- Revenue Next Year
- POOL $4.88
- ENVB N/A
- P/E Ratio
- POOL $28.18
- ENVB N/A
- Revenue Growth
- POOL N/A
- ENVB N/A
- 52 Week Low
- POOL $284.27
- ENVB $1.01
- 52 Week High
- POOL $395.60
- ENVB $222.75
- Technical
- Relative Strength Index (RSI)
- POOL 47.71
- ENVB 31.20
- Support Level
- POOL $293.79
- ENVB $1.23
- Resistance Level
- POOL $309.49
- ENVB $1.40
- Average True Range (ATR)
- POOL 9.61
- ENVB 0.09
- MACD
- POOL 1.37
- ENVB 0.16
- Stochastic Oscillator
- POOL 50.73
- ENVB 46.62
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.